Analysts See $-0.33 EPS for Unum Therapeutics Inc. (UMRX)

July 14, 2018 - By Robert Sims

Analysts expect Unum Therapeutics Inc. (NASDAQ:UMRX) to report $-0.33 EPS on August, 13.After having $-0.66 EPS previously, Unum Therapeutics Inc.’s analysts see -50.00 % EPS growth. The stock increased 5.48% or $0.84 during the last trading session, reaching $16.16. About 78,054 shares traded. Unum Therapeutics Inc. (NASDAQ:UMRX) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company has market cap of $482.20 million. The Company’s lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. It currently has negative earnings. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers.

More important recent Unum Therapeutics Inc. (NASDAQ:UMRX) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018, also Nasdaq.com published article titled: “Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the …”, Bizjournals.com published: “Goodwin dominates this year’s record batch of Mass. biotech IPOs” on July 03, 2018. More interesting news about Unum Therapeutics Inc. (NASDAQ:UMRX) was released by: Globenewswire.com and their article: “Unum Therapeutics Joins Russell 3000® Index” with publication date: June 25, 2018.

Unum Therapeutics Inc. (NASDAQ:UMRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: